Have a feature idea you'd love to see implemented?
Let us know!
KNSA Kiniksa Pharmaceuticals Ltd
Price (delayed)
$18.34
Market cap
$1.32B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.13
Enterprise value
$1.24B
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's portfolio of
Highlights
Kiniksa Pharmaceuticals's revenue has surged by 54% YoY and by 13% QoQ
KNSA's gross profit has surged by 52% year-on-year and by 11% since the previous quarter
KNSA's net income is down by 36% year-on-year but it is up by 11% since the previous quarter
The EPS has declined by 18% year-on-year but it is up by 13% since the previous quarter
KNSA's quick ratio is down by 32% YoY and by 9% QoQ
Key stats
What are the main financial stats of KNSA
Market
Valuations
Earnings
Shares outstanding
72.2M
Market cap
$1.32B
Enterprise value
$1.24B
Price to book (P/B)
2.99
Price to sales (P/S)
3.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.22
Revenue
$384.1M
Gross profit
$331.5M
Net income
-$9.07M
EBIT
-$16.72M
EBITDA
-$11.78M
Free cash flow
$11.13M
Per share
Balance sheet
Liquidity
EPS
-$0.13
EPS diluted
-$0.13
Free cash flow per share
$0.16
Book value per share
$6.13
Revenue per share
$5.36
TBVPS
$7.51
Total assets
$555.3M
Total liabilities
$118.29M
Debt
$10.6M
Equity
$437.01M
Working capital
$215.35M
Debt to equity
0.02
Current ratio
3.24
Quick ratio
2.59
Net debt/EBITDA
7.37
Margins
Efficiency
Dividend
EBITDA margin
-3.1%
Gross margin
86.3%
Net margin
-2.4%
Operating margin
-6.8%
Return on assets
-1.7%
Return on equity
-2.1%
Return on invested capital
-4.9%
Return on capital employed
-3.6%
Return on sales
-4.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KNSA stock price
How has the Kiniksa Pharmaceuticals stock price performed over time
Intraday
0.94%
1 week
-8.3%
1 month
-9.21%
1 year
-2.81%
YTD
-7.28%
QTD
-7.28%
Financial performance
How have Kiniksa Pharmaceuticals's revenue and profit performed over time
Revenue
$384.1M
Gross profit
$331.5M
Operating income
-$26.24M
Net income
-$9.07M
Gross margin
86.3%
Net margin
-2.4%
Kiniksa Pharmaceuticals's revenue has surged by 54% YoY and by 13% QoQ
KNSA's gross profit has surged by 52% year-on-year and by 11% since the previous quarter
KNSA's operating income is down by 36% year-on-year but it is up by 4.6% since the previous quarter
KNSA's net income is down by 36% year-on-year but it is up by 11% since the previous quarter
Growth
What is Kiniksa Pharmaceuticals's growth rate over time
Valuation
What is Kiniksa Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.99
P/S
3.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.22
The EPS has declined by 18% year-on-year but it is up by 13% since the previous quarter
KNSA's price to book (P/B) is 15% lower than its 5-year quarterly average of 3.5 and 9% lower than its last 4 quarters average of 3.3
Kiniksa Pharmaceuticals's equity has increased by 8% YoY
Kiniksa Pharmaceuticals's revenue has surged by 54% YoY and by 13% QoQ
The stock's price to sales (P/S) is 22% less than its last 4 quarters average of 4.4
Efficiency
How efficient is Kiniksa Pharmaceuticals business performance
Kiniksa Pharmaceuticals's return on equity has decreased by 24% YoY but it has increased by 13% QoQ
KNSA's ROIC is down by 23% YoY but it is up by 11% from the previous quarter
Kiniksa Pharmaceuticals's return on assets has decreased by 21% YoY but it has increased by 15% QoQ
The return on sales is up by 17% since the previous quarter and by 10% year-on-year
Dividends
What is KNSA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KNSA.
Financial health
How did Kiniksa Pharmaceuticals financials performed over time
KNSA's total liabilities has surged by 52% year-on-year and by 10% since the previous quarter
Kiniksa Pharmaceuticals's current ratio has decreased by 32% YoY and by 9% from the previous quarter
The debt is 98% smaller than the equity
The debt to equity has contracted by 33% from the previous quarter and by 33% YoY
The debt has declined by 18% year-on-year and by 7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.